LOGO
LOGO

TransMedics Q4 Results Trump Estimates, Provides Rosy Outlook

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024

Shares of TransMedics Group Inc. (TMDX) are up over 20% at $96 in premarket trading Tuesday, thanks to stellar financial results for the quarter and year ended December 31, 2023.

This medical technology company has developed technologies to preserve organ quality and assess organ viability prior to transplant for patients with end-stage lung, heart, and liver failure.

For the fourth quarter of 2023, the company generated a net income of $4.0 million or $0.12 per share on total revenue of $81.2 million. This compares with a net loss of $6.7 million or $0.21 per share and total revenue of $31.4 million in the year-ago fourth quarter.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -June 15 - June 19, 2026

June 19, 2026 16:46 ET
Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.

RELATED NEWS